Antiatherogenic Properties of tert-Butylhydroquinone

Award Information
Agency:
Department of Health and Human Services
Amount:
$100,000.00
Program:
STTR
Contract:
1R41HL076925-01
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
N/A
Award Year:
2004
Phase:
Phase I
Agency Tracking Number:
HL076925
Solicitation Topic Code:
N/A
Small Business Information
BIOINVENTIONS, LLC
BIOINVENTIONS, LLC, 2109 W MARKET ST, STE 120, JOHNSON CITY, TN, 37604
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 WILLIAM STONE
 (423) 439-8762
 stone@etsu.edu
Business Contact
 WILLIAM STONE
Phone: (423) 439-8762
Email: BILLSTON@BIOINVENTIONSLLC.COM
Research Institution
 EAST TENNESSEE STATE UNIVERSITY
 EAST TENNESSEE STATE UNIVERSITY
Johnson City, TN, 37601
 Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): Atherosclerosis is the underlying cause of most cardiovascular disease and considerable evidence supports the role of hypercholesterolemia as a risk factor for this disease. In preliminary work, we found that tertiary-butyl hydroquinone (TBHQ), at a dose lower than approved for human use, was effective in reducing plasma levels of both total cholesterol and triglycerides in a rat model. TBHQ is phenolic antioxidant commonly used as a food preservative. A patent, "Method for Reducing Blood Cholesterol and/or Blood Triglycerides," was subsequently obtained. The long-term objective of this research proposal is to determine the antiatherogenic potential of TBHQ and advance its commercial development. Our specific aims are to test the efficacy of TBHQ in: (1) reducing aortic atherosclerosis; (2) lowering plasma lipid levels; (3) promoting a less atherogenic lipoprotein profile and; (4) reducing plasma levels of C-reactive protein (CRP). Elevated levels of CRP are a risk factor for cardiovascular disease. In our phase I experiments, we will use the apoE knockout (apoE-/-) mouse model since it has been extensively used to study the antiatherogenic potential of other phenolic antioxidants. Our preliminary market analysis suggests that TBHQ could have a potential market of $100 million per year as a lipid-lowering agent. Commercial development should be accelerated since NIH has already conducted extensive toxicological studies with TBHQ.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government